6GJ Stock Overview
An ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Glaukos Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$80.50 |
| 52 Week High | US$152.00 |
| 52 Week Low | US$72.50 |
| Beta | 0.83 |
| 1 Month Change | 3.87% |
| 3 Month Change | -44.10% |
| 1 Year Change | -19.50% |
| 3 Year Change | 112.96% |
| 5 Year Change | 136.76% |
| Change since IPO | 224.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6GJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 4.7% | 0.8% |
| 1Y | -19.5% | -8.9% | 14.6% |
Return vs Industry: 6GJ underperformed the German Medical Equipment industry which returned -8.9% over the past year.
Return vs Market: 6GJ underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| 6GJ volatility | |
|---|---|
| 6GJ Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 6GJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6GJ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 995 | Tom Burns | www.glaukos.com |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system.
Glaukos Corporation Fundamentals Summary
| 6GJ fundamental statistics | |
|---|---|
| Market cap | €4.89b |
| Earnings (TTM) | -€110.93m |
| Revenue (TTM) | €362.82m |
13.5x
P/S Ratio-44.1x
P/E RatioIs 6GJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6GJ income statement (TTM) | |
|---|---|
| Revenue | US$404.52m |
| Cost of Revenue | US$98.09m |
| Gross Profit | US$306.44m |
| Other Expenses | US$430.12m |
| Earnings | -US$123.68m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | 75.75% |
| Net Profit Margin | -30.57% |
| Debt/Equity Ratio | 0% |
How did 6GJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 02:05 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Glaukos Corporation is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Ravi Misra | Berenberg |
| Joanne Wuensch | BMO Capital Markets Equity Research |